empagliflozin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases body mass index
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The random‐effects analysis of four RCTs comprising 315 patients with MASLD showed that Empagliflozin significantly reduced BMI (WMD −0.71 kg/m2; 95% CI: −1.00 to −0.43, p < 0.001) and showed negligible heterogeneity (I 2 = 0%).”
Quoted verbatim from Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 10 mg/day
- Population
- Adults with MASLD (previously NAFLD or NASH), with or without type 2 diabetes; four RCTs
Effect -0.71 mean difference, 95% CI -1 to -0.43
Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.2026PMID:42504019Permalink
Keep reading
- Everything the graph holds on empagliflozin
- Every compound studied against Body mass index
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45EE36MD44C02CVQZ20QDS0